Business Context and Reporting Period
Company: Bioanalytical Systems, Inc. (Note: Input metadata referenced "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended June 30, 2001
Business Overview: The Company supports drug development by providing products and research services globally to pharmaceutical and biotechnology firms. Operations are divided into two segments: analytical services (chemistry support) and products (liquid chromatography, electrochemical, and physiological monitoring equipment).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2001 | Nine Months Ended June 30, 2001 | Balance Sheet June 30, 2001 |
|---|---|---|---|
| Total Revenue | $6.40 million | $18.67 million | - |
| Gross Profit | $3.10 million | $8.99 million | - |
| Operating Income | $0.97 million | $2.58 million | - |
| Net Income | $0.52 million | $1.29 million | - |
| Cash & Equivalents | - | - | $0.40 million |
| Working Capital | - | - | $2.47 million |
| Debt (Current) | - | - | $1.09 million |
| Debt (Long-Term) | - | - | $3.29 million |
Margins (Nine Months 2001): Gross Margin was 48.2%; Operating Margin was 13.8%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 17.4% for the quarter and 33.5% for the nine months compared to the prior year periods. This was driven primarily by a surge in services revenue (up 46.1% for the quarter) due to additional bioanalytical, preclinical, and pharmaceutical contracts.
- Profitability Turnaround: The Company reported a net income of $0.52 million for the quarter and $1.29 million for the nine months, reversing net losses of $0.14 million and $0.94 million, respectively, in the prior year periods.
- Cost Efficiency: Cost of services revenue as a percentage of revenue improved significantly, dropping from 90.1% to 65.4% for the quarter, attributed to higher-margin contract work.
- Cash Flow: Net cash provided by operating activities turned positive at $2.79 million for the nine months ended June 30, 2001, compared to a use of $0.74 million in the prior year.
- Debt Reduction: The outstanding balance on the revolving line of credit decreased significantly, reducing interest expense.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes cash generated from operations and the existing $3.5 million line of credit (with $615,000 outstanding) are sufficient to fund working capital and capital expenditure requirements.
- Capital Expenditures: The Company spent $0.88 million on property and equipment for the nine months, primarily for facility expansion and laboratory equipment. No firm commitments for future capital expenditures were disclosed.
- Accounting Changes: The Company noted the upcoming adoption of SFAS No. 141 and 142 regarding goodwill. Application of non-amortization provisions is expected to increase net income by approximately $77,000 annually starting in fiscal year 2003.
- Legal Proceedings: A patent infringement lawsuit filed by CMA Microdialysis Holding A.B. regarding microdialysis probes was settled in the quarter ended December 31, 2000, for an immaterial amount.
- Tax Rate: The effective tax rate increased to 42.5% for the quarter (from 35.0% prior year) due to nondeductible foreign losses.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 46% increase in services revenue and the mix of new contracts driving this growth.
- Debt Covenants: Confirm the Company is maintaining the financial ratios required by its $3.5 million line of credit and commercial mortgage.
- Cash Position: Monitor the cash balance of $400,000 relative to the $1.09 million in current liabilities to assess short-term liquidity.
- Goodwill Impairment: Watch for the results of the first annual impairment test for goodwill under new accounting standards (SFAS 142) upon adoption.
- Product Mix: Assess the continued performance of the "Culex" automated blood sampling devices and "epsilon" family products cited as revenue drivers.